奥氮平与利培酮治疗首发精神分裂症的疗效及安全性  

Clinical efficacy and safety of olanzapine and risperidone in the treatment of first episode schizophrenia

作　　者：杨老虎[1] 魏昆岭[1] 苏顺英[1] 高良会[1] 成玉敏[1] 

机构地区：[1]河北省精神卫生中心精神科,河北保定071000

出　　处：《中国临床药理学杂志》2010年第9期647-649,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的评价奥氮平与利培酮治疗首发精神分裂症的疗效及安全性。方法 96例首发精神分裂症患者随机分为奥氮平组与利培酮组,分别治疗8周。采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)评定疗效及副反应。结果奥氮平组与利培酮组的总有效率分别为81.67%和79.36%,差异无统计学意义(P>0.05)。2组不良反应发生率低、程度轻,奥氮平组体质量增加比例高于利培酮组;利培酮组锥体外系反应比例高于奥氮平组。结论 2种药物均为疗效好、安全性高的抗精神病药。Objective To evuluate the clinical efficacy and safety of olanzapine and risperidone in the treatment of first episode schizophrenia. Methods Ninty six patients with diagnosis of first episode schizophrenia were randomly assigned to two groups that were treated with olanzapine and risperidone for 8 weeks, respectively. The therapeutic response and side effects were evaluated with PANSS （Positive and Negative Syndrome Scale） overall and TESS（ Treatment Emergent Symptom Scale）. Results The effective rate of olanzapine and risperidone were 81.67% and 79.36% , respectively （ P 〉 0. 05 ） During the treatment, the two groups effects were less and milder. Olanzapine was associated with more weight gain and risperidone with more EPS （extrapyramidal syndrome） . Conclusion The two drugs are efficacy and safety antipsychotic drugs in treatment of first episode schizophrenia

关 键 词：奥氮平 利培酮 首发精神分裂症 

分 类 号：R971.4[医药卫生—药品] R749.3[医药卫生—药学]